Welcome to the EPA 2022 Interactive Programme 

The congress will officially run on Central European Summer Time (CEST/GMT +2) 

To convert the congress times to your local time Click Here 

Icon

Description automatically generatedFully Live with Live Q&A Icon

Description automatically generatedOn Demand (available from 4 June)  Icon

Description automatically generatedECP Session 

Icon

Description automatically generatedSection Session Icon

Description automatically generatedEPA Course (Pre-Registration Required)   Ask the Expert

Displaying One Session

Session Type
Industry
Date
Mon, 06.06.2022
Session Time
19:00 - 20:00
Room
Industry session hall 1
Session Description
Advances in insomnia care – the importance of daytime functioning -Supported by Idorsia Pharmaceuticals Ltd

Session Description:

Chronic insomnia disorder is the most common sleep–wake disorder worldwide. It is a 24-hour condition with symptoms that affect patients’ nighttime and daytime functioning, presenting a significant burden for patients and healthcare systems. It has a negative effect on many aspects of daily living, such as reducing workplace productivity, and increasing risk of injuries and motor vehicle accidents. Insomnia is also associated with serious long-term health conditions, including psychiatric disorders, cardiovascular diseases and type 2 diabetes. Current treatment approaches for chronic insomnia disorder may not adequately address the needs of all aspects of the condition. This industry-sponsored symposium will examine the impact of chronic insomnia disorder with a focus on daytime functioning. Furthermore, this expert faculty will explore the mechanism of the disease as a causal target for the treatment of this condition and review the data from pivotal clinical trials of daridorexant - a next-generation dual orexin receptor antagonist for the treatment of chronic insomnia disorder. .

Welcome and introduction

Session Type
Industry
Date
Mon, 06.06.2022
Session Time
19:00 - 20:00
Room
Industry session hall 1
Lecture Time
19:00 - 19:05

Insomnia: a 24-hour condition with an impact on sleep and daytime functioning

Session Type
Industry
Date
Mon, 06.06.2022
Session Time
19:00 - 20:00
Room
Industry session hall 1
Lecture Time
19:05 - 19:20

The orexin system: a causal target for insomnia treatment

Session Type
Industry
Date
Mon, 06.06.2022
Session Time
19:00 - 20:00
Room
Industry session hall 1
Lecture Time
19:20 - 19:35

Daridorexant phase 3 data: the next-generation dual orexin receptor antagonist

Session Type
Industry
Date
Mon, 06.06.2022
Session Time
19:00 - 20:00
Room
Industry session hall 1
Lecture Time
19:35 - 19:50

Panel discussion and close

Session Type
Industry
Date
Mon, 06.06.2022
Session Time
19:00 - 20:00
Room
Industry session hall 1
Lecture Time
19:50 - 20:00